Table 2 Gait Assessment
From: Rivastigmine improves dual-task gait velocity in patients with Alzheimer’s disease
Baseline | 12 weeks | p-value (12 weeks vs. baseline) | |
|---|---|---|---|
Rivastigmine | 0 mg | 18 mg/day | |
Single-task gait trials | |||
Normal gait (mean, SD) | |||
velocity (m/min) | 59.21 (12.21) | 59.82 (11.46) | 0.733 |
stride length (cm) | 50.11 (7.52) | 51.68 (7.27) | 0.111 |
cadence (steps/min) | 117.69 (12.26) | 115.55 (13.26) | 0.412 |
Fast gait (mean, SD) | |||
velocity (m/min) | 70.33 (16.06) | 69.44 (12.62) | 0.691 |
stride length (cm) | 54.64 (8.58) | 55.5 (7.95) | 0.367 |
cadence (steps/min) | 127.69 (13.37) | 125.11 (13.17) | 0.406 |
Dual-task gait trials | |||
Counting backward by 7 s | |||
velocity (m/min) | 40.59 (13.59) | 46.88 (12.73) | 0.025* |
stride length (cm) | 46 (9.29) | 46.37 (6.61) | 0.716 |
cadence (steps/min) | 89.37 (24.64) | 99.35 (18.02) | 0.048* |
Naming animals | |||
velocity (m/min) | 37.06 (15.57) | 42.03 (14.02) | 0.036* |
stride length (cm) | 46.25 (9.24) | 47.55 (7.46) | 0.199 |
cadence (steps/min) | 80.46 (27.15) | 88.76 (23.42) | 0.076 |